CytoReason

These days we’re seeing leading venture firms and key strategic partners investing billons of dollars in AI companies focused on improving patient care, drug development, and clinical efficiency. For example, Spring Health recently secured $100 million to develop the company’s AI platform which matches patients with appropriate care providers and treatment plans. Amazon Web Services (AWS) and GE HealthCare are collaborating to leverage AI models to enhance standard of care in the healthcare sector. And in CytoReason's case, NVIDIA, Pfizer, Thermo Fisher Scientific, OurCrowd, and others are investing in our computational models, so we can develop more disease models in more therapeutic areas, address diverse patient populations with molecular and clinical data, and ultimately empower decision-makers with AI tools intended to help them increase the probability of phase 2 success. https://lnkd.in/dBp9FUuQ

CytoReason just closed $80 million in Series B! Among the investors are three of the world's leading companies – NVIDIA, Pfizer, and Thermo Fisher Scientific. Why did these industry leaders invest in CytoReason? And why now? Let me explain with a story from the past. On January 24, 1848, James Marshall accidentally found gold in the American River. The news of the discovery sparked the California Gold Rush, bringing 300,000 people from across the US and beyond. But only a few struck it rich. Truth be told, gold panning seldom yielded anything of substantial value. Enter Levi Strauss, an immigrant from Bavaria. In 1853, he opened a dry goods company in San Francisco, recognizing a need for durable clothing and tools among hardworking miners. This is the origin story of Levi’s blue jeans. Strauss empowered the miners. He gave them the tools and clothing to increase the probability of finding gold. As an individual, he brought more value and made more impact than any one gold miner. In pharma, the gold is the new drug. The mine is the data. There’s plenty of data, and it just keeps growing at an amazing pace. What’s sorely missing is interpretation at scale – a better understanding of the disease biology and of the treatment landscape – major barriers for precision medicine. We founded CytoReason eight years ago to bridge this gap. Our work was based on my lab’s research at the Technion - Israel Institute of Technology, where we developed innovative algorithms to systematically get more bang for the buck from biological data. CytoReason’s goal was always the same. Not to find gold, but - like Levi Strauss' contribution to the miners - to EMPOWER scientists and decision-makers with the tools to increase the probability of developing successful drugs. We built the computational disease model to integrate multi-modal data, simulate disease biology, and predict treatment effects. This investment will help CytoReason build more disease models in more therapeutic areas. It will improve the accuracy of our existing models with proprietary data from new partnerships, just like our partnership with the Crohn's & Colitis Foundation. None of this would be possible without the Technion’s belief in a strong academic-industry engagement – which ensures that innovation makes real-world impact. I want to thank David H., CytoReason’s co-founder and CEO, and co-founders Elina Starosvetsky, Renaud Gaujoux, Ksenya Kveler and Yuval Kalugny for their vision in making CytoReason what it is today. Special thanks to CytoReason employees (Cytos). They’re the ones building complex models and transformative technology. I’m aware of the personal sacrifices they make. I deeply appreciate their dedication. And of course, thank you NVIDIA, Pfizer, Thermo Fisher, OurCrowd, and Asymmetry Ventures, for your trust in CytoReason. This is a big day for CytoReason, drug developers, and patients worldwide. Read press release here: https://lnkd.in/euKUAQAG

Exciting news at CytoReason! Today we’re announcing the closing of our Series B round, backed by some of the world's leading companies. Thank you, NVIDIA, Pfizer and Thermo Fisher Scientific – together with our existing partners at OurCrowd and Asymmetry Ventures – for this vote of confidence in our people, our technology, and our business. Why CytoReason, and why now? BECAUSE OF THE TECHNOLOGY “Over the last year, CytoReason has strengthened its platforms using NVIDIA’s latest accelerated computing and AI platforms, achieving more than 10x acceleration for inference workloads. Our continued collaboration with CytoReason will help enable more life sciences companies to benefit from CytoReason’s predictive clinical insights.” -- Kimberly Powell, Vice President and General Manager, Healthcare at NVIDIA BECAUSE OF THE DATA "Our investment in CytoReason underscores the significant potential of computational disease models to revolutionize data usage in pharma R&D. By combining Thermo Fisher’s vast data repositories and proven life sciences expertise with CytoReason’s AI technology, we aim to push the boundaries of what is possible in personalized healthcare.” -- Bhooshi De Silva, Head of Strategic Capital at Thermo Fisher AND BECAUSE OF THE POTENTIAL “The rapid expansion of new technologies, like artificial intelligence, holds tremendous potential to help transform what is possible in human health. Our collaboration with CytoReason leverages its cutting-edge immunology multiomics platform to augment Pfizer’s own R&D capabilities and generate invaluable insights into new drug development pathways for patients. -- Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development and Medical at Pfizer Read more about the raise here: https://lnkd.in/dU5YrCYp This is a gread day for CytoReason and the industry. Now let's get back to work!

Exciting news at CytoReason! Today we’re announcing the closing of our Series B round, backed by some of the world's leading companies. Thank you, NVIDIA, Pfizer and Thermo Fisher Scientific – together with our existing partners at OurCrowd and Asymmetry Ventures – for this vote of confidence in our people, our technology, and our business. Why CytoReason, and why now? BECAUSE OF THE TECHNOLOGY “Over the last year, CytoReason has strengthened its platforms using NVIDIA’s latest accelerated computing and AI platforms, achieving more than 10x acceleration for inference workloads. Our continued collaboration with CytoReason will help enable more life sciences companies to benefit from CytoReason’s predictive clinical insights.” -- Kimberly Powell, Vice President and General Manager, Healthcare at NVIDIA BECAUSE OF THE DATA "Our investment in CytoReason underscores the significant potential of computational disease models to revolutionize data usage in pharma R&D. By combining Thermo Fisher’s vast data repositories and proven life sciences expertise with CytoReason’s AI technology, we aim to push the boundaries of what is possible in personalized healthcare.” -- Bhooshi De Silva, Head of Strategic Capital at Thermo Fisher AND BECAUSE OF THE POTENTIAL “The rapid expansion of new technologies, like artificial intelligence, holds tremendous potential to help transform what is possible in human health. Our collaboration with CytoReason leverages its cutting-edge immunology multiomics platform to augment Pfizer’s own R&D capabilities and generate invaluable insights into new drug development pathways for patients. -- Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development and Medical at Pfizer Read more about the raise here: https://lnkd.in/dU5YrCYp This is a gread day for CytoReason and the industry. Now let's get back to work!

We're #hiring a new Bioinformatics Scientist in Tel Aviv District. Apply today or share this post with your network.

We're #hiring a new Immunologist in Tel Aviv District. Apply today or share this post with your network.

Good things happen when CytoReason co-founder Shai Shen-Orr puts on his teaching hat and delves into the systems immunology mindset, alongside brilliant industry professionals such as Angela Hadjipanayis. Gets even better when our longtime partner at Sanofi, Emanuele de Rinaldis, orchestrates this important event together with Magnus Fontes of Institut Roche, at the annual meeting of the Federation of Clinical Immunology Societies (FOCIS). Science discourse at its best.

Come meet us at the Biotech Career Fair! Sunday, July 14 Weizmann Institute of Science

Our Director of Science, Roye Rozov, has just celebrated his 5th year anniversary at CytoReason. Hailing from both the US and Israel, Roye's journey blends his passion for biology with his expertise in computer science, math, and physics. In his own words: "There's this thing DNA, and cells are basically the little computers, and DNA is like the operating system, and the different programs that the cells run basically encode for everything that we are." That's classic Roye – proud to have him pioneering our scientific efforts.

We're #hiring an Immunologist! As an immunologist at CytoReason you will work closely with our expanding multi-disciplinary team of biologists, software engineers, and bioinformaticians. You’ll tackle the pharmaceutical industry’s most burning questions using cutting-edge data analysis techniques. You’ll decipher disease mechanisms, identify biomarkers, look for novel drug targets and develop new approaches for the computational modeling of disease in the pharma industry.   This role is customer-facing, and successful candidates should have a passion for clear and effective communication of scientific research. You’ll accompany the world’s top pharma companies as they enter the era of precision medicine and as they make groundbreaking discoveries and bring novel therapies to patients who most need them. Responsibilities: 🔍 You will interact regularly with top pharma scientists to define the scope, approach and deliverables of a research project 🔍 Become the biology domain expert in the projects you participate in 🔍 Perform data interpretation and analysis 🔍 Build a plan with an internal team and manage the research project. 🔍 Participate in discussions that define the key questions, scope and output of a data analysis project 🔍 Administrative and scientific leadership, including presenting the progress of the project and delivering reports to the clients Requirements  📕 PhD in Immunology or systems biology or related field  📕 Proven track record of successful teamwork and research collaboration  📕 Experience in building biological hypotheses using high dimensional data  📕 Ability to quickly develop expertise in any given biological/disease domain  📕 Very strong communication skills in English 📕 Excellent presentation skills   Advantages 🔦 3+ years Post-doctoral training, preferred outside Israel 🔦 Experience in commercial pharma R&D and drug development 🔦 Experience with multiple omics technologies 🔦 Strong data affinity and experience with high throughput data analysis and interpretation Please send your CV to join@cytoreason.com